| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
S&D Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩31,850.00 |
| 52 Week High | ₩45,800.00 |
| 52 Week Low | ₩12,690.00 |
| Beta | 1.05 |
| 1 Month Change | -4.21% |
| 3 Month Change | 72.63% |
| 1 Year Change | 110.79% |
| 3 Year Change | -18.85% |
| 5 Year Change | 130.80% |
| Change since IPO | 610.14% |
Recent News & Updates
Is Now An Opportune Moment To Examine S&D Co., Ltd (KOSDAQ:260970)?
Apr 23
S&D Co., Ltd's (KOSDAQ:260970) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Mar 18Shareholder Returns
| A260970 | KR Chemicals | KR Market | |
|---|---|---|---|
| 7D | -1.4% | -5.1% | -3.1% |
| 1Y | 110.8% | -20.6% | 1.5% |
Return vs Industry: A260970 exceeded the KR Chemicals industry which returned -19.2% over the past year.
Return vs Market: A260970 exceeded the KR Market which returned 2.9% over the past year.
Price Volatility
| A260970 volatility | |
|---|---|
| A260970 Average Weekly Movement | 16.0% |
| Chemicals Industry Average Movement | 4.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A260970's share price has been volatile over the past 3 months.
Volatility Over Time: A260970's weekly volatility has increased from 9% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Kyung-Mok Yeo | www.isnd.co.kr |
S&D Co., Ltd develops and sells health functional food in South Korea. The company offers general functional food ingredients, health-oriented functional ingredients, and biological industry materials for the sleeping problems and glycoconjugate gastric functions. It provides health-oriented functional ingredients, such as Lindera glauca extract, Rice bran Extract, MPG-6/MPGT, RCS, and Xanthorrhizol, as well as other materials, including Pagopyridol, SD 1002F, and Panduratin.
S&D Co., Ltd Fundamentals Summary
| A260970 fundamental statistics | |
|---|---|
| Market cap | ₩92.13b |
| Earnings (TTM) | ₩12.66b |
| Revenue (TTM) | ₩93.88b |
7.3x
P/E Ratio1.0x
P/S RatioIs A260970 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A260970 income statement (TTM) | |
|---|---|
| Revenue | ₩93.88b |
| Cost of Revenue | ₩71.91b |
| Gross Profit | ₩21.98b |
| Other Expenses | ₩9.32b |
| Earnings | ₩12.66b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.38k |
| Gross Margin | 23.41% |
| Net Profit Margin | 13.48% |
| Debt/Equity Ratio | 0% |
How did A260970 perform over the long term?
See historical performance and comparison